KG, 3 Department of Medical Sciences, Division of Gastroenterology, University of Turin, 4 The Texas Liver Institute, University of Texas Health San Antonio, and Arizona Liver Health, 5 Boehringer Ingelheim International GmbH, 6 Department of Internal Medicine II, Saarland University Medical Center, 7 National Institute for Health Research Biomedical Research Centre, University Hospital Birmingham, 8 Faculty of Medical Sciences, Newcastle University, 9 Covenant Metabolic Specialists, LLC, 10 Texas Liver Institute, University of Texas Health San Antonio, 11 The Institute of Cardiometabolism and Nutrition, Sorbonne Universit, Hpital PitiSalptrire, 12 Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 13 Boehringer Ingelheim Pharmaceuticals, Inc., 14 Virginia Commonwealth University Background: We evaluated non-invasive liver biomarkers from a phase II trial of survodutide, a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis
AS: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Supervision, Visualization, Writing original draft, Writing review & editing
Because acarbose has limited systemic absorption, which results in minimal maternal plasma concentrations, clinically significant exposure via breast milk is not expected
Vision loss in uveitis
